InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (11 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
11
T+90 hit rate
73%
T+90 mean return
+8.1%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Kewalramani Reshma, Chairman & CEO. Director active across 2 companies, notably Vertex Pharmaceuticals INC / MA. Aggregated, 37 disclosures have been recorded. Split: 2 buys · 11 sells. Total volume traded: €45.7m. Activity tracked since 19 August 2021. The latest transaction was disclosed on 26 February 2025 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Declarations37 total
14,079 shares@ US$479.617.6% of flowCommon StockSEC:0000875320-25-000131:0
9,386 shares@ US$483.285.1% of flowCommon StockSEC:0000875320-25-000111:0
6,553 shares@ US$463.463.4% of flowCommon StockSEC:0000875320-25-000089:0
19,015 shares0Common StockSEC:0000875320-25-000067:0
8,300 shares@ US$467.984.5% of flowCommon StockSEC:0000875320-25-000044:0
29,118 shares0Common StockSEC:0000875320-25-000018:0
15,198 shares@ US$515.008.6% of flowCommon StockSEC:0000875320-24-000225:0
15,202 shares@ US$505.008.4% of flowCommon StockSEC:0000875320-24-000195:0
15,202 shares@ US$497.008.2% of flowCommon StockSEC:0000875320-24-000187:0
105,263 sharesClass A Common StockSEC:0001127602-24-018713:0
1,565 shares@ US$187.530.3% of flowCommon StockSEC:0000875320-24-000160:0
15,202 shares@ US$447.007.4% of flowCommon StockSEC:0000875320-24-000156:0
9,386 shares@ US$431.794.4% of flowCommon StockSEC:0000875320-24-000105:0
9,359 shares@ US$424.014.4% of flowCommon StockSEC:0000875320-24-000074:0
8,255 shares@ US$422.743.8% of flowCommon StockSEC:0000875320-24-000051:0
14,516 shares0Common StockSEC:0000875320-24-000026:0
3,058 shares@ US$155.570.5% of flowCommon StockSEC:0000875320-23-000062:0
5,098 shares@ US$397.002.2% of flowCommon StockSEC:0000875320-23-000058:0
5,097 shares@ US$377.002.1% of flowCommon StockSEC:0000875320-23-000035:0
7,828 shares@ US$355.002.9% of flowCommon StockSEC:0001209191-23-042557:0
1,611 shares@ US$338.690.6% of flowCommon StockSEC:0001209191-23-026270:0
9,386 shares@ US$289.123.0% of flowCommon StockSEC:0001209191-23-013718:0
9,359 shares@ US$292.853.0% of flowCommon StockSEC:0001209191-23-011686:0
3,372 shares@ US$294.331.1% of flowCommon StockSEC:0001209191-23-009198:0
12,388 shares0Common StockSEC:0001209191-23-006946:0
25 of 37 declarations
About Kewalramani Reshma
Reshma Kewalramani is the CEO & President and Board Member at Vertex Pharmaceuticals Inc. and Ginkgo Bioworks Holdings, Inc. She oversees the operations of both companies and is responsible for the overall strategy. Her leadership is essential for growth and innovation in the biopharmaceutical sector.
